secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001649094-25-000057
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte appoints Dr. Olivier Brandicourt to board of directors
--------------------------------------------------------------

- Appointment effective May 1, 2025 as a Class III director with term expiring at 2026 annual meeting.
- Board determined Dr. Brandicourt qualifies as independent under Nasdaq rules.
- Receives initial equity award of $800,000 in nonstatutory stock options vesting over 36 months.
- Annual cash retainer of $50,000 and annual equity award of $450,000 (75% option, 25% RSU).
- Standard indemnification agreement entered; no reportable transactions per Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000057/0001649094-25-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000057/pcvx-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001649094-25-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer